Uromigos-ASCO GU
Michiel Van der Heijden, MD, PhD, joined The Uromigos to review bladder cancer research from the 2023 ASCO GU Symposium.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Matt Galsky, MD discusses updates for the CheckMate 274 Trial at the 2023 ASCO GU Cancers Symposium with The Uromigos.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
Christian Kollmannsberger, MD, FRCPC, discusses his presentation on utilizing miR371 as a biomarker for germ cell tumors.
Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC.
Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use.
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the IMvigor130 study.
Andrea Necchi, MD describes the results of the phase 2 KEYNOTE-057 study at the 2023 ASCO GU Cancers Symposium.
Axel Bex, MD, PhD, from the Netherlands Cancer Institute, Amsterdam, described results of the NeoAvAx trial as ...
Dr. Fred Saad describes the results of the PROpel Phase III trial.
Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial.
Dr Petros Grivas describes the results of this phase 2 trial.
Kim Chi, MD, describes the results of the MAGNITUDE trial,
Results from the ARASENS trial appear to have confirmed triple therapy as the new standard of care for mHSPC.
Pete Nelson, MD, describes mechanism of action and current clinical application in prostate cancer.
670 Madison Ave.
Manalapan, NJ 07726